erlotinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1045 183321-74-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • erlotinib hydrochloride
  • tarceva
  • erlotinib
  • CP-358,774-01
  • OSI-774
  • erlotinib HCl
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.
  • Molecular weight: 393.44
  • Formula: C22H23N3O4
  • CLOGP: 4.19
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 74.73
  • ALOGS: -4.64
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.40 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.45 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 59 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.77 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.69 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 18, 2004 FDA OSI PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 5509.92 19.69 2779 19214 332769 46331300
Disease progression 872.40 19.69 539 21454 90761 46573308
Rash 765.68 19.69 885 21108 355627 46308442
Diarrhoea 524.15 19.69 936 21057 558666 46105403
Malignant neoplasm progression 426.43 19.69 304 21689 64622 46599447
Dermatitis acneiform 321.49 19.69 106 21887 3964 46660105
Lung neoplasm malignant 237.73 19.69 125 21868 15364 46648705
Metastases to central nervous system 196.56 19.69 99 21894 11122 46652947
Dry skin 191.67 19.69 157 21836 40859 46623210
Drug resistance 163.74 19.69 102 21891 17266 46646803
Paronychia 158.79 19.69 65 21928 4501 46659568
Neoplasm malignant 153.88 19.69 110 21883 23389 46640680
Incorrect dose administered 150.03 19.69 143 21850 45407 46618662
Non-small cell lung cancer 141.74 19.69 54 21939 3090 46660979
Decreased appetite 110.42 19.69 266 21727 193570 46470499
Lung adenocarcinoma 107.05 19.69 48 21945 4156 46659913
Lung cancer metastatic 92.22 19.69 37 21956 2431 46661638
Drug hypersensitivity 85.81 19.69 8 21985 243817 46420252
Acne 78.13 19.69 69 21924 19850 46644219
Pleural effusion 76.69 19.69 139 21854 82813 46581256
Metastasis 75.36 19.69 38 21955 4274 46659795
Hair growth abnormal 74.16 19.69 32 21961 2526 46661543
Pancreatic carcinoma metastatic 69.41 19.69 30 21963 2378 46661691
Dehydration 65.45 19.69 194 21799 159346 46504723
Headache 64.03 19.69 79 21914 478273 46185796
Arthralgia 60.39 19.69 50 21943 364553 46299516
Non-small cell lung cancer metastatic 56.22 19.69 18 21975 611 46663458
Skin fissures 52.67 19.69 37 21956 7643 46656426
Growth of eyelashes 52.51 19.69 13 21980 167 46663902
Acquired gene mutation 52.49 19.69 17 21976 599 46663470
Condition aggravated 52.38 19.69 25 21968 245027 46419042
Joint swelling 52.10 19.69 8 21985 166065 46498004
Malignant pleural effusion 49.92 19.69 24 21969 2434 46661635
Stomatitis 49.14 19.69 103 21890 68194 46595875
EGFR gene mutation 49.07 19.69 12 21981 146 46663923
Alopecia scarring 47.79 19.69 11 21982 101 46663968
Skin toxicity 46.33 19.69 26 21967 3628 46660441
Naevoid melanoma 44.13 19.69 7 21986 3 46664066
Metastases to lung 43.84 19.69 38 21955 10658 46653411
Multiple-drug resistance 43.06 19.69 22 21971 2543 46661526
Metastases to bone 41.41 19.69 46 21947 17430 46646639
Drug ineffective 41.40 19.69 172 21821 677666 45986403
Trichiasis 41.14 19.69 9 21984 64 46664005
Hair texture abnormal 40.83 19.69 22 21971 2834 46661235
Metastases to liver 40.42 19.69 48 21945 19537 46644532
Rash pustular 39.83 19.69 30 21963 6899 46657170
Haemoptysis 39.59 19.69 55 21938 26134 46637935
Injection site pain 39.06 19.69 3 21990 107149 46556920
Sinusitis 36.93 19.69 8 21985 129760 46534309
Skin exfoliation 36.71 19.69 60 21933 32878 46631191
Eye irritation 36.42 19.69 42 21951 16572 46647497
Weight increased 36.33 19.69 16 21977 164457 46499612
Pancreatic carcinoma 34.64 19.69 27 21966 6530 46657539
Nasopharyngitis 33.98 19.69 15 21978 153983 46510086
Metastatic neoplasm 33.58 19.69 21 21972 3572 46660497
Interstitial lung disease 31.63 19.69 75 21918 53874 46610195
Pain in extremity 31.18 19.69 46 21947 258634 46405435
Erythema dyschromicum perstans 31.16 19.69 7 21986 57 46664012
Metastases to spine 31.01 19.69 18 21975 2676 46661393
Metastases to meninges 30.82 19.69 16 21977 1911 46662158
Therapy partial responder 30.82 19.69 22 21971 4660 46659409
Pulmonary embolism 29.41 19.69 115 21878 108470 46555599
Arthropathy 29.17 19.69 3 21990 84697 46579372
Dysphagia 28.82 19.69 91 21902 77221 46586848
Product dose omission issue 27.97 19.69 23 21970 168497 46495572
Lung adenocarcinoma stage IV 27.87 19.69 8 21985 186 46663883
Metastases to neck 26.92 19.69 6 21987 47 46664022
Henoch-Schonlein purpura 26.85 19.69 12 21981 1030 46663039
Psoriasis 26.52 19.69 3 21990 78601 46585468
Toxicity to various agents 26.15 19.69 37 21956 211729 46452340
Nausea 26.07 19.69 461 21532 686993 45977076
Asthma 25.32 19.69 6 21987 91536 46572533
Palpitations 24.90 19.69 7 21986 95252 46568817
Onychalgia 24.89 19.69 10 21983 659 46663410
Pyogenic granuloma 24.38 19.69 8 21985 294 46663775
Hirsutism 24.19 19.69 11 21982 983 46663086
Corneal perforation 23.92 19.69 9 21984 497 46663572
Neoplasm progression 23.72 19.69 44 21949 26639 46637430
Blepharitis 23.36 19.69 14 21979 2207 46661862
Peripheral swelling 23.35 19.69 24 21969 158047 46506022
Pain 23.21 19.69 131 21862 476817 46187252
Performance status decreased 23.14 19.69 16 21977 3221 46660848
Conjunctivitis 22.72 19.69 32 21961 15392 46648677
Onychoclasis 22.56 19.69 19 21974 5125 46658944
Lymphangiosis carcinomatosa 22.54 19.69 11 21982 1153 46662916
Feeling abnormal 22.10 19.69 16 21977 125044 46539025
Laryngeal papilloma 21.93 19.69 4 21989 9 46664060
Pneumatosis intestinalis 21.92 19.69 13 21980 2012 46662057
Vomiting 21.74 19.69 316 21677 452478 46211591
Blood bilirubin increased 21.66 19.69 49 21944 34135 46629934
Skin disorder 21.43 19.69 38 21955 22225 46641844
Pneumothorax 21.03 19.69 30 21963 14599 46649470
Metastases to breast 20.77 19.69 7 21986 280 46663789
Migraine 20.57 19.69 4 21989 70022 46594047
Ulcerative keratitis 20.43 19.69 13 21980 2280 46661789
Asthenia 20.38 19.69 230 21763 310845 46353224
Iridocele 19.98 19.69 3 21990 0 46664069
Hypersensitivity 19.83 19.69 25 21968 150296 46513773
Dry eye 19.81 19.69 44 21949 30278 46633791
Weight decreased 19.73 19.69 168 21825 210681 46453388

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 5696.35 17.99 3299 17673 353984 29577522
Rash 900.75 17.99 869 20103 191020 29740486
Disease progression 757.52 17.99 545 20427 79329 29852177
Dermatitis acneiform 255.95 17.99 109 20863 5580 29925926
Malignant neoplasm progression 243.98 17.99 276 20696 72011 29859495
Diarrhoea 212.98 17.99 611 20361 333492 29598014
Neoplasm malignant 199.36 17.99 135 20837 17679 29913827
Lung neoplasm malignant 189.47 17.99 123 20849 15009 29916497
Non-small cell lung cancer 166.22 17.99 71 20901 3659 29927847
Dehydration 101.41 17.99 249 20723 123290 29808216
Metastases to central nervous system 100.55 17.99 63 20909 7221 29924285
Incorrect dose administered 94.98 17.99 114 20858 31572 29899934
Non-small cell lung cancer metastatic 87.11 17.99 27 20945 545 29930961
Lung adenocarcinoma 81.77 17.99 45 20927 4054 29927452
Interstitial lung disease 76.55 17.99 145 20827 60052 29871454
Haemoptysis 74.42 17.99 100 20872 30978 29900528
Decreased appetite 63.89 17.99 240 20732 149670 29781836
Lung cancer metastatic 59.54 17.99 31 20941 2497 29929009
Drug resistance 57.96 17.99 71 20901 20062 29911444
Pancreatic carcinoma 57.33 17.99 46 20926 7791 29923715
Acne 53.84 17.99 48 20924 9388 29922118
Pleural effusion 53.09 17.99 142 20830 73924 29857582
Metastasis 46.71 17.99 29 20943 3269 29928237
Toxicity to various agents 46.24 17.99 34 20938 177149 29754357
EGFR gene mutation 44.70 17.99 11 20961 89 29931417
Skin toxicity 44.58 17.99 28 20944 3221 29928285
Neoplasm progression 40.11 17.99 56 20916 17967 29913539
Malignant pleural effusion 39.46 17.99 19 20953 1295 29930211
Metastases to lung 38.89 17.99 37 20935 7858 29923648
Paronychia 36.49 17.99 24 20948 2987 29928519
Drug ineffective 35.64 17.99 121 20851 340266 29591240
Pancreatic carcinoma metastatic 34.85 17.99 24 20948 3223 29928283
Gastrointestinal perforation 34.79 17.99 25 20947 3591 29927915
Bradycardia 34.74 17.99 3 20969 65523 29865983
Acute kidney injury 33.92 17.99 90 20882 273752 29657754
Product dose omission issue 33.83 17.99 11 20961 91620 29839886
Lymphangiosis carcinomatosa 33.04 17.99 15 20957 894 29930612
Product use in unapproved indication 32.74 17.99 6 20966 73687 29857819
Pneumoperitoneum 32.69 17.99 18 20954 1622 29929884
Pneumothorax 32.64 17.99 48 20924 16145 29915361
Dizziness 31.65 17.99 55 20917 194854 29736652
Weight increased 31.40 17.99 7 20965 74906 29856600
Metastases to bone 30.98 17.99 36 20936 9622 29921884
Metastases to liver 30.93 17.99 40 20932 11925 29919581
Metastases to spine 29.83 17.99 19 20953 2239 29929267
Rash pustular 29.72 17.99 26 20946 4957 29926549
Drug hypersensitivity 29.54 17.99 6 20966 68513 29862993
Vomiting 29.45 17.99 258 20714 219560 29711946
Pneumonitis 28.71 17.99 61 20911 27393 29904113
Arthralgia 27.25 17.99 33 20939 135758 29795748
Pulmonary embolism 25.23 17.99 115 20857 78020 29853486
Stomatitis 25.20 17.99 70 20902 37209 29894297
Overdose 24.95 17.99 14 20958 84323 29847183
Metastases to meninges 23.46 17.99 13 20959 1186 29930320
Hyperhidrosis 23.14 17.99 9 20963 67081 29864425
Lung carcinoma cell type unspecified stage IV 23.05 17.99 9 20963 367 29931139
Condition aggravated 22.26 17.99 39 20933 137827 29793679
Myocardial infarction 21.71 17.99 34 20938 125591 29805915
Tremor 21.59 17.99 13 20959 75350 29856156
Nausea 21.59 17.99 309 20663 296648 29634858
Bronchial fistula 21.52 17.99 7 20965 166 29931340
Therapy partial responder 21.50 17.99 19 20953 3672 29927834
Oesophageal ulcer 21.38 17.99 18 20954 3259 29928247
Mucosal inflammation 21.35 17.99 58 20914 30436 29901070
Insomnia 20.56 17.99 21 20951 93315 29838191
Nasopharyngitis 20.12 17.99 8 20964 58841 29872665
Rhabdomyolysis 19.61 17.99 10 20962 63570 29867936
Headache 19.56 17.99 64 20908 182242 29749264
Blood pressure increased 18.47 17.99 14 20958 71914 29859592
Hypophagia 18.35 17.99 45 20927 22191 29909315
Growth of eyelashes 18.32 17.99 5 20967 63 29931443
Skin reaction 18.21 17.99 19 20953 4506 29927000
Dry skin 18.07 17.99 45 20927 22409 29909097
Conjunctivitis 18.01 17.99 25 20947 7975 29923531

Pharmacologic Action:

SourceCodeDescription
ATC L01EB02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:37699 protein kinase inhibitors
CHEBI has role CHEBI:74440 egfr inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908
Adenocarcinoma of pancreas indication 700423003 DOID:4074
Hyperbilirubinemia contraindication 14783006 DOID:2741
Myocardial infarction contraindication 22298006 DOID:5844
Dehydration contraindication 34095006
Hypokalemia contraindication 43339004
Hepatorenal syndrome contraindication 51292008 DOID:11823
Fibrosis of lung contraindication 51615001 DOID:3770
Gastrointestinal perforation contraindication 51875005
Hemolytic anemia contraindication 61261009 DOID:583
Interstitial pneumonia contraindication 64667001
Blood coagulation disorder contraindication 64779008 DOID:1247
Adult respiratory distress syndrome contraindication 67782005 DOID:11394
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Kidney disease contraindication 90708001 DOID:557
Corneal ulcer contraindication 91514001 DOID:8463
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Cerebrovascular accident contraindication 230690007
Interstitial lung disease contraindication 233703007 DOID:3082
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Smokes tobacco daily contraindication 449868002
Obstructive Bronchiolitis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase INHIBITOR IC50 9.22 WOMBAT-PK CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.15 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.72 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 5.03 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.14 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase Kd 5.24 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.37 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6.89 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 7.24 CHEMBL
Serine/threonine-protein kinase MRCK gamma Kinase Kd 5.47 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.36 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.04 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6.70 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 5.89 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 5.74 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.72 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.96 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.30 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 5.96 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.77 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.39 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 5.59 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.51 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.92 CHEMBL
Aurora kinase A Kinase Kd 5.66 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.02 CHEMBL
Casein kinase I isoform delta Kinase Kd 5.46 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase 4 Kinase Kd 5.60 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 5.51 CHEMBL
Vascular endothelial growth factor receptor 3 Kinase Kd 5.68 CHEMBL
AarF domain-containing protein kinase 4 Kinase Kd 5.60 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.16 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.96 CHEMBL
Death-associated protein kinase 3 Kinase Kd 5.22 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.70 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.03 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.43 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.07 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.72 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.15 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.36 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.48 CHEMBL
Myotonin-protein kinase Kinase Kd 5.54 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.10 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 5.41 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.66 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.60 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 6.01 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 6.05 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.60 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.02 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.40 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.24 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.54 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.74 CHEMBL
Aurora kinase C Kinase Kd 6.22 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.08 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 5.42 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 5.85 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.72 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 5.92 CHEMBL
Citron Rho-interacting kinase Kinase Kd 6.17 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 5.64 CHEMBL
Misshapen-like kinase 1 Kinase Kd 5.89 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 5.54 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.36 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 5.89 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 6.64 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 5.20 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.36 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.35 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 5.19 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 5.15 CHEMBL
Aurora kinase B Kinase Kd 5.85 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.59 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.62 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 5.85 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.31 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.28 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.15 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 6.01 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.96 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.20 CHEMBL
Solute carrier organic anion transporter family member 2B1 Unclassified INHIBITOR Ki 6.28 IUPHAR
Tubulin alpha-1A chain Structural Kd 6.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.20 CHEMBL

External reference:

IDSource
D04023 KEGG_DRUG
183319-69-9 SECONDARY_CAS_RN
4021511 VANDF
C1533491 UMLSCUI
CHEBI:114785 CHEBI
AQ4 PDB_CHEM_ID
CHEMBL1079742 ChEMBL_ID
CHEMBL553 ChEMBL_ID
DB00530 DRUGBANK_ID
D000069347 MESH_DESCRIPTOR_UI
176871 PUBCHEM_CID
4920 IUPHAR_LIGAND_ID
8133 INN_ID
J4T82NDH7E UNII
337525 RXNORM
19073 MMSL
248186 MMSL
63773 MMSL
d05412 MMSL
008759 NDDF
008760 NDDF
414122006 SNOMEDCT_US
414123001 SNOMEDCT_US
426686007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 0093-7663 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 0093-7664 TABLET, FILM COATED 150 mg ORAL ANDA 24 sections
Erlotinib Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7131 TABLET, FILM COATED 25 mg ORAL ANDA 26 sections
Erlotinib Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7132 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Erlotinib Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7133 TABLET, FILM COATED 150 mg ORAL ANDA 26 sections
TARCEVA HUMAN PRESCRIPTION DRUG LABEL 1 50242-062 TABLET 25 mg ORAL NDA 24 sections
TARCEVA HUMAN PRESCRIPTION DRUG LABEL 1 50242-063 TABLET 100 mg ORAL NDA 24 sections
TARCEVA HUMAN PRESCRIPTION DRUG LABEL 1 50242-064 TABLET 150 mg ORAL NDA 24 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 51991-890 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 51991-891 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 51991-892 TABLET, FILM COATED 150 mg ORAL ANDA 28 sections
Tarceva HUMAN PRESCRIPTION DRUG LABEL 1 54868-5290 TABLET 25 mg ORAL NDA 20 sections
Tarceva HUMAN PRESCRIPTION DRUG LABEL 1 54868-5447 TABLET 150 mg ORAL NDA 20 sections
Tarceva HUMAN PRESCRIPTION DRUG LABEL 1 54868-5474 TABLET 100 mg ORAL NDA 20 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 59923-725 TABLET, FILM COATED 25 mg ORAL ANDA 28 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 59923-726 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 59923-727 TABLET, FILM COATED 150 mg ORAL ANDA 28 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 63304-095 TABLET, FILM COATED 25 mg ORAL ANDA 26 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 63304-096 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 63304-135 TABLET, FILM COATED 150 mg ORAL ANDA 26 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 68382-913 TABLET 25 mg ORAL ANDA 23 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 68382-914 TABLET 100 mg ORAL ANDA 23 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 68382-915 TABLET 150 mg ORAL ANDA 23 sections
Erlotinib Hydrochloride Human Prescription Drug Label 1 69539-090 TABLET, FILM COATED 25 mg ORAL ANDA 24 sections
Erlotinib Hydrochloride Human Prescription Drug Label 1 69539-091 TABLET, FILM COATED 100 mg ORAL ANDA 24 sections
Erlotinib Hydrochloride Human Prescription Drug Label 1 69539-092 TABLET, FILM COATED 150 mg ORAL ANDA 24 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 70771-1521 TABLET, FILM COATED 25 mg ORAL ANDA 1 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 70771-1522 TABLET, FILM COATED 100 mg ORAL ANDA 1 sections
Erlotinib HUMAN PRESCRIPTION DRUG LABEL 1 70771-1523 TABLET, FILM COATED 150 mg ORAL ANDA 1 sections
Erlotinib Hydrochloride Human Prescription Drug Label 1 72205-080 TABLET, FILM COATED 25 mg ORAL ANDA 24 sections